Pharmacovigilance Market Is Set To Reach $15,259.8 Million by 2030

1
Pharmacovigilance Market Is Set To Reach
15,259.8 Million by 2030
2
The global pharmacovigilance market is expected
to reach 15,259.8 million by 2030 from 6,724.2
million in 2021, growing at a CAGR of 9.5 during
20212030. In 2021, based on therapeutic area,
the oncology category held a 27 share. Due to
the side-effects of cancer drugs, monitoring
their safety is extremely important. In this
regard, pharmacovigilance aids in detecting,
managing, and even preventing adverse drug
reactions and limiting the requirement for
needless medical prescriptions. The high patient
compliance for drug usage, rising concerns
regarding drug safety, and growing incidence of
toxicity and ADRs propel the pharmacovigilance
market growth. Moreover, non-government and
government organizations are focusing on drug
efficacy and safety, which is compelling drug
developers and entities conducting medical trials
to avail of pharmacovigilance services. Get the
sample pages of this report at
https//www.psmarketresearch.com/market-analysis/p
harmacovigilance-market/report-sample
3
Key Findings of Pharmacovigilance Market
Report During the projection period, the APAC
region is predicted to expand at the highest
rate, of about 10.6, owing to the improving
healthcare infrastructure, rising incidence of
chronic pain in regional countries, and
increasing drug development activities. In
2021, phase IV clinical trials accounted for more
than 70 of the revenue in the product lifecycle
category. This was due to the high number of
clinical trials conducted to assess a new drug's
effectiveness and safety, wherein the fourth
phase is the most critical. The spontaneous
reporting technique had the biggest
pharmacovigilance market share in 2021. Because
of its widespread usage in detecting important,
novel, and uncommon ADRs, along with its
cost-effectiveness and efficiency, this technique
finds wide adoption. Novartis AG reported
clinical data on JDQ443, an experimental
selective, covalent, and orally accessible
KRASG12C inhibitor, in April 2022. KontRASt-01
(NCT04699188) is a multi-center, phase Ib/II
open-label dosage escalation trial of JDQ443 in
patients with advanced solid tumors having the
KRAS G12C mutation, such as NSCLC and colorectal
cancer.
4
By Process Flow Case Data Management Signal
Detection Risk Management System By Therapeutic
Area Oncology Neurology Cardiology Pulmono
logy By End Use Pharmaceuticals Biotechnology
Companies Medical Device Manufacturers
Pharmacovigilance Market Segmentation Analysis By
Product Life Cycle Pre-Clinical Phase
I Phase II Phase III Phase IV By Service
Provider In-House Third Parties By
Type Spontaneous Reporting Intensified ADR
Reporting Targeted Spontaneous
Reporting Cohort Event Monitoring EHR Mining
5
Asia-Pacific (APAC) o China o India o Japan o A
ustralia o South Korea Latin America o Brazil o
Mexico Middle East and Africa o Saudi
Arabia o South Africa
By Region North America o U.S. o Canada Europe
o Germany o France o U.K. o Italy o Spain
Browse detailed report on Pharmacovigilance
Market Size, Share, Growth and Demand Forecast to
2030_at_ https//www.psmarketresearch.com/market-anal
ysis/pharmacovigilance-market
6
Disclaimer PS Intelligence always keeps its
customers interests at the core while carrying
out research activities. PS Intelligence ensures
the reliability and accuracy of information and
data provided in its market research
publications. However, the information in
publications is subject to fluctuations, as it is
based on primary interviews of officials from
various companies or organizations. PS
Intelligence is not responsible for any incorrect
data provided by the key industry players of the
concerned domain. the information or analysis in
PS Intelligence publications represents opinions
based on research and should not be interpreted
as statements of fact. Information in this report
was believed to be correct at the time of
publication, but cannot be guaranteed. PS
Intelligence does not endorse any product,
service, or vendor depicted in its research
publications. All intellectual properties,
including trademarks and copyrights, belong to
their respective owners and may be protected by
copyright. Under no circumstance can these be
reproduced in any form without prior written
agreement of their owners. An order for market
research report is intended for internal use of
the company only and not for disclosure to third
parties or any other publication in general. No
service, report, or part thereof provided by PS
Intelligence can be reproduced, republished,
resold, revealed, distributed, circulated, or
sublicensed in any medium or form now realized or
hereafter become realized, including but not
limited to, all forms of optical-based media,
magnetic, electronic, or digital, without a
written permission from Prescient Strategic
Intelligence Pvt. Ltd.